Comparative pharmacology of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
There are 5 BCR/ABL tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML): bosutinib, ponatinib, imatinib, nilotinib and dasatinib. The availability of several therapeutic options raises the possibility of individualizing patient treatment. When evaluating patients’...
| Main Authors: | , , |
|---|---|
| Format: | info:eu-repo/semantics/article |
| Language: | eng |
| Published: |
Graphy
2022
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10171/64793 |